Area of research
Epidemiology · Hepatology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Alcohol Consumption and Health Effects, and Liver Diseases and Immunity.
Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden
Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes
Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease
Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD
From “Burnt-Out” to “Burning-Out”: Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction–Associated Steatotic Liver Disease From a Dynamic Perspective
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease
Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD
The People-First Liver Charter
Use of new CORE risk score to predict 10 year risk of liver cirrhosis in general population: population based cohort study
Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD
Emerging Role of Phosphatidylethanol Testing in Clinical Practice for the Identification of Steatotic Liver Disease Subtypes: Is This the New Standard?
Association between longitudinal weight change and clinical outcome in individuals with MASLD
Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD
Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes
Adverse pregnancy and birth outcomes in women with biopsy-proven MASLD: a nationwide cohort study
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study
FIB-4-based Referral Pathways Have Suboptimal Accuracy to Identify Increased Liver Stiffness and Incident Advanced Liver Disease
IDDF2025-ABS-0058 Longitudinal changes in fibrosis markers: monitoring stiffness/fibrosis progression and prognostic outcomes in metabolic dysfunction-associated steatotic liver disease
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease
Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis
Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes
Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
Developing and validating clinical prediction models in hepatology – An overview for clinicians